Prestige Biopharma is one of the fastest growing biopharmaceuticals specialising in the discovery and development of first-in-class antibody drugs, biosimilars, and vaccines.

Established in July 2015, we have been committed to developing first-in-class antibody drugs to address unmet medical needs including pancreatic cancer, as well as developing high-quality and cost-competitive biosimilars to enhance patient access to affordable treatments for critical diseases. In addition, we have entered research and development of next-generation vaccines against future pandemics.

With decades of R&D and operational experience on top of scientific capabilities, we expedite future biologics development and commercialization throughout the world, based in our headquarter in Singapore, IDC (Innovative Discovery Centre) in Busan, Korea, the hub of R&D, and Prestige Biologics, CDMO (Contract Development Manufacturing Organisation) wing in Osong, Korea, as well as partnerships with global pharmaceuticals.